超声内镜引导下射频消融与手术切除治疗胰腺胰岛素瘤的比较
该多中心回顾性研究经倾向匹配比较超声内镜引导下射频消融(EUS-RFA)与手术切除治疗散发性胰腺胰岛素瘤的安全性与疗效。匹配后每组89例,EUS-RFA组不良事件率18.0%低于手术组61.8%,无严重不良事件而手术组为15.7%;临床有效率分别为95.5%与100%,无显著差异;EUS-RFA组随访更短、住院更短,16.9%病灶复发。
要点
- 匹配后EUS-RFA组不良事件率18.0%,低于手术组的61.8%(P < .001)。
- EUS-RFA组无严重不良事件,手术组严重不良事件率为15.7%(P < .0001)。
- 临床有效率EUS-RFA组95.5% vs 手术组100%,无显著差异(P = .160)。
核心结论
- EUS-RFA治疗胰腺胰岛素瘤比手术更安全且高度有效;若经随机研究证实,EUS-RFA可成为散发性胰腺胰岛素瘤的一线治疗。
研究设计与样本
- 回顾性识别2014年至2022年在23个中心接受EUS-RFA或8家高容量胰腺手术机构接受手术切除的散发性胰腺胰岛素瘤患者,采用倾向匹配分析比较结局,主要结局为安全性。
主要发现
- 倾向评分匹配后每组89例(1:1),两组在年龄、性别、Charlson合并症指数、美国麻醉医师协会评分、体重指数、病灶与主胰管距离、病灶部位、大小和分级方面分布均衡。
- 不良事件率EUS-RFA组18.0% vs 手术组61.8%(P < .001);EUS-RFA组无严重不良事件,手术组严重不良事件率15.7%(P < .0001)。
- 临床有效率手术组100% vs EUS-RFA组95.5%(P = .160)。
- EUS-RFA组随访时间更短(中位23个月,四分位距14-31个月 vs 手术组37个月,四分位距17.5-67个月;P < .0001)。
- 住院时间手术组显著更长(11.1 ± 9.7天 vs EUS-RFA组3.0 ± 2.5天;P < .0001);EUS-RFA后15个病灶(16.9%)复发,接受再次EUS-RFA(11例)或手术切除(4例)均成功。
临床怎么用
- 作者认为EUS-RFA比手术更安全且高度有效;若经随机研究证实,EUS-RFA可成为散发性胰腺胰岛素瘤的一线治疗。
局限性
- EUS-RFA组随访时间更短(中位23个月,四分位距14-31个月 vs 手术组37个月,四分位距17.5-67个月;P < .0001)。
- 原文结论提出需经随机研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is emerging as a safe and effective treatment for pancreatic neuroendocrine tumors. We aimed to compare EUS-RFA and surgical resection for the treatment of pancreatic insulinoma (PI). METHODS: Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis. Primary outcome was safety. Secondary outcomes were clinical efficacy, hospital stay, and recurrence rate after EUS-RFA. RESULTS: Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160). However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients). CONCLUSION: EUS-RFA is safer than surgery and highly effective for the treatment of PI. If confirmed in a randomized study, EUS-RFA treatment can become first-line therapy for sporadic PI.
引用
- Crinò SF, Napoleon B, Facciorusso A, et al. Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clin Gastroenterol Hepatol. 2023. PMID: 36871765. doi:10.1016/j.cgh.2023.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。